PEG Biosciences Inc

Live Well & Live Longer

We are committed to developing high quality, life-saving medicines for unmet medical needs in humans.

Home

Innovative Technology Targeted to Unmet Medical Needs

PEG Biosciences Inc (PBI), a biotechnology company located in New Jersey USA, specializes in the development of innovative therapeutics targeted to unmet medical needs based on its proprietary BioSynersys™ and ProbioTherapeutic™ technologies.

PBI focuses on novel drug delivery technology to create first-in-class and best-in-class drugs for the treatment of disease with particular emphasis in the fields of cancer, and infectious and autoimmune disease.[

PBI’s business model is centered on the development of best-in-class new drugs and the reformulation of existing biological drugs based on its proprietary technology.  The Company considers partnering and selling products to pharmaceutical and biotechnology companies for clinical studies and commercialization.

PBI’s advanced BioSynersys™ and ProbioTherapeutic™ drug delivery technology can be leveraged to help pharmaceutical and biotechnology partners develop and realize the full potential of their products.  The PBI team is dedicated to working to create the next breakthrough medicine.

Leadership

Chyi Lee, Ph.D – Founder, President and CEO – Dr. Lee is the inventor of
BioSynersys™ and ProbioTherapeutics™ platform technologies. He has developed four FDA approved drugs, including PEG-Intron®, Oncaspar®, Adagen® and Oncoscint®. Dr. Lee has over 36 years of experience in the pharmaceutical industry, held various key managerial positions at several publicly traded companies ,and is an expert in the development of Pegylated drugs. Dr. Lee has extensive experience in drug discovery and development as well as CMC regulatory affairs. Prior to starting PEG Biosciences, Dr. Lee was an independent pharmaceutical consultant providing project oversight, problem solving and product development for a number of pharmaceutical and biotechnology companies, including Johnson & Johnson. He spent 14 years with Enzon Pharmaceuticals. At Enzon, he developed three commercial Pegylated drugs and a number of experimental products for clinical trials. Earlier in his career, Dr. Lee developed various monoclonal antibody-conjugate products for cancer imaging and therapy at Cytogen. His research interests center on the development of innovative drug delivery technology, particularly relating to the improvement of Pegylation. This has created a groundbreaking PEG-biologic platform that was invented to harness the full potential of biologics for therapy for the treatment of life-threatening diseases.

PEG Biosciences Inc (PBI), a biotechnology company located in New Jersey USA, specializes in the development of innovative therapeutics targeted to unmet medical needs based on its proprietary BioSynersys™ and ProbioTherapeutic™ technologies.

Yuh-geng Tsay, Ph.D. - Chair of the Business Development Committee and the former Group President of Thermo Fisher Scientific. Dr. Tsay brings over 38 years of experience in the health industry as a corporate officer, senior executive and health industry leader with extensive corporate management, strategic planning, business development, marketing and financing practice in the global health industry. Dr. Tsay was Senior Vice President and Group President, Specialty Diagnostics of Thermo Fisher Scientific, Inc. Prior to Thermo’s merger with Fisher, he was Fisher’s Group President of Immunodiagnostics. Dr. Tsay previously led the immunodiagnostics business within Apogent Technologies, which was acquired by Fisher in 2004. Dr. Tsay held a variety of executive positions including President and CEO of Microgenics Corporation, founder and CEO of Diagnostics Reagents, Inc. (DRI®), founder of Yellowstone Diagnostic Corporation, VP, R&D of 3M Diagnostic Systems, and also VP, R&D of International Immunoassay Labs. He serves as a Board Member of a number of organizations that include AltheaDx, ReadCoor and Bonraybio. 

Richard C. Siegel, Ph.D. – Board Member and Chair of the Drug Development and Manufacture Committee. Dr. Siegel has over 35 years of experience in the
pharmaceutical industry as a senior executive and global pharmaceutical industry
leader with extensive experience in drug development and manufacture, corporate management and strategic planning. He had a broad experience in CMC and drug development, including monoclonal antibodies, therapeutic proteins and conjugates, peptides, oligonucleotides, cellular products and small molecule drugs. Dr. Siegel was the former Vice President and Global Head of Portfolio Management, Janssen R&D, a former Johnson & Johnson Company. He also held various executive positions in Johnson & Johnson Pharmaceutical Companies, including Vice President of API Technical Operations, GPSG; Vice President of Pharmaceutical Development, Centocor; and Executive Director of Pharmaceutical Development, Centocor. 

Kwok Shum, Ph.D. – Dr. Shum serves as Senior Vice President for Preclinical
Development. He has more than 36 years of experience in the pharmaceutical industry with extensive experience in preclinical drug development in the area of oncology, parasitology, antiviral and antibiotics. Dr. Shum held key managerial positions at various companies with scientific responsibilities for pharmacology, toxicology and regulatory affairs. He was the former Vice President of Preclinical Development of Bridge Pharmaceuticals. Dr. Shum held senior management positions in a number of public companies, including Intermune Inc., Enzon Pharmaceuticals, Robert Pharmaceutical and Schering-Plough Corporation.

Chialang Grand Huang, Ph.D. - Dr. Huang serves as Vice President of Chemistry and New Product Development. He has more than 34 years of experience in the pharmaceutical industry with extensive experience in drug discovery and development. Dr. Huang held key positions at various companies with scientific responsibilities for drug discovery, scale-up, chemical manufacturing processes and controls, formulation and analytical development, method and process validation, stability programs, CMC, regulatory compliance as well as technology transfers. He held senior positions in a number of pharmaceutical companies, including Baxter Healthcare Corporation, Lonza Inc. and Ohmeda Pharmaceutical Products Division of BOC Group. 

Technology

A Breakthrough in Drug Delivery Technology

BioSynersys™ is PBI’s breakthrough technology platform that can be used to optimize biologics to create best-in-class therapeutics.

BioSynersys™ constitutes a new generation biologic platform and provides a unique toolkit for protein conjugation to create powerful synergistic biologics.  The novel synergistic biologics provide increased biological activities, reduced toxicity and synergistically enhanced pharmacological properties for maximizing therapeutic efficacy.  Additionally, BioSynersys™ provides a new drug delivery avenue for biologics that suffer a dramatic loss of their biological activities after being Pegylated with conventional PEG reagents.

Peptides and short-lived biologics are rapidly metabolized, have low bioavailability, and have a short circulatory half-life.  These undesirable properties make them unlikely to be used as a medicine.  ProbioTherapeutic™, a unique site-specific conjugation technology, is capable of creating effective therapeutic compositions to turn short-lived peptides or biologics into clinically important medicines.

PBI intends to develop new generation Synergy PEG-enhanced drugs from the existing biological drugs based on BioSynersys™ and ProbioTherapeutic™.  BioSynersys™ and ProbioTherapeutic™ platforms were invented to maximize and realize the full potential of therapeutic biologics for creating effective medicines.

Intellectual Property
PBI seeks to protect its technology by pursuing patents related to advances in drug delivery that are essential to the development of the company’s novel therapeutic drugs.

Issued US Patent: 9,364,553
Issued Chinese Patent: CN 103068853 B
Synergistic Biomolecule-Polymer Conjugates

R&D Pipeline

Your Partner in Pharmaceutical Development

PBI is dedicated to the development of therapeutics for the treatment of life-threatening diseases. The Company’s immuno-oncology PB307 biologic is designed to promote and harness the body’s own immune system to destroy cancer cells.  PB307 has been demonstrated in animal models to show dramatically increased tumor infiltrating lymphocytes (TILs) in tumor, significantly decreased immunosuppressive components in tumor, and tumor microenvironment modulation for enhancing cancer immunotherapy.

PB307 is an immuno-oncology drug, a formula developed leveraging years of research and development from the immune responses in cancer therapy.  PB307 is designed to inhibit the growth of cancer cells and to strengthen the body’s immune system to promote a sustained and enhanced immune response to attack cancers without side effects.  PB307 target indications include pancreatic, breast, colorectal, gastric, brain, liver, ovarian, lung and other cancers.

PB121 is an immune-oncology therapeutic.  The improved PB121 cytokine formulation is developed to specifically activate NK cells and T effector cells as well as to overcome immunosuppressive components of the tumor microenvironment.

PB718 is developed for drug addiction treatment.  This anti-addiction product is designed to prevent people who have certain drug addictions (e.g., opioids) from taking them again.  For opioid addiction, it works in the brain to reduce and further prevent opiate effects.  PB718 is formulated to reduce the symptoms of opiate withdrawal and minimize patient discomfort during the detox duration.  PB718 is a novel next generation therapeutic providing solutions to treat both pain and addiction.

PB922 is an anti-inflammatory biological product.  PB922 formulation is an enhanced biological system consisting of regulation of cytokines production and T cell proliferation.  It is developed for the treatment of autoimmune diseases, including multiple sclerosis, Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.

PB844 is a specially formulated naturally occurring biologic and is developed for the treatment of neurologic disorders and neurodegenerative diseases.

PB1018 is an immunotherapeutic biologic being developed for the treatment of viral infections.

PBI utilizes BioSynersys™ to develop new generation Synergy PEG-enhanced drugs from the existing biological drugs.
PB1103 is the synergy interferon-alfa developed based on BioSynersys™ for the treatment of cancers, blood disorders and viral diseases.  Synergy interferon-alfa can enhance a patient’s immune response to cancer cells and may also inhibit the growth of cancer cells. PB1103 is expected to be an effective biological therapeutics for the treatment of various cancers, including kidney, melanoma, Kaposi sarcoma, hairy cell leukemia (HCL), myeloid leukemia (CML) and hematologic cancers.
Also, synergy interferon-alfa provides increased and sustained antiviral activity plus synergistically enhanced pharmacological properties and has been demonstrated to be superior to the commercial Pegylated interferon-alfa.  PB1103 is a new generation interferon therapeutic for viral infections, including hepatitis B and hepatitis C.

Commercial Product

DevirusNature

devirusnature.com

Natural Antiviral Nasal Sanitizer – Powered by Plants

DevirusNature is the first botanical-formulated natural nasal drops having broad-spectrum antimicrobial (antiviral and antibacterial) properties and is made in the USA. It is safe, works immediately and is backed by science. DevirusNature is formulated to remove viruses in the upper airways, preventing viruses from incubating and spreading to the lower respiratory tract or throughout the systems of the body which cause systemic infections.

Nature supports human health. We believe that nature has solutions to humans’ important problems, such as the pandemic. The solutions that already exist in nature need to be discovered and used. DevirusNature is formulated with natural ingredients to remove invading viruses in nasal and respiratory passages as well as to enhance airway epithelium immune functions against viral infection and inflammation. Apply DevirusNature topically in nose to stop virus entering body system and keep nasal passageway clean, lubricated, virus-free and sinuses clear.

Please see the detail of DevirusNature on weblink: www.devirusnature.com

Partnering

PBI selectively pursues collaborations to accelerate the commercialization of its pipeline.  The Company also welcomes the opportunity to discuss with potential partners, the ways that its technology can help to create the next breakthrough medicine.

PBI’s BioSynersys™ and ProbioTherapeutic™ platform technologies along with its process know-how are available to partners for the development of next generation therapeutics.  Working with PBI offers access to its unique Synergy PEG reagents. 

In instances where a promising product suffers disappointment after applying conventional Pegylation, a valuable product is limited by the current Pegylation method, or a product encounters any of the problems, such as short half-life, frequent or high dosing, toxicity, immunogenicity, stability, and solubility, PBI is able to offer a solution that could help partners realize the full potential of their products.

Product & Technology Partnership Opportunities:
PBI’s two core products and BioSynersys™ technology platform are available for partnership opportunities:

PB307 opens up a new realm of anticancer immunotherapy.  PB307 has the potential to be a powerful immune-oncology drug.  In addition to inhibiting tumor growth without drug resistance and adverse effects, the PB307 formula offers other advantages as an immunotherapeutic drug:
· PB307 could be an effective immunotherapeutic drug for prophylaxis of cancer recurrence.
· PB307 has potential to be an anticancer drug with multiple cancer indications, including pancreatic cancer, colorectal cancer, gastric cancer, lung cancer, gastric cancer, head and neck cancer, ovarian cancer, lung cancer, etc.


PB1103, a synergy interferon-alfa, has increased, sustained and prolonged biological activity in blood plasma.  PB1103 is expected to be an effective biotherapy for the treatment of various cancers, including kidney, melanoma, Kaposi sarcoma, hairy cell leukemia (HCL), myeloid leukemia (CML) and hematologic cancers.  PB1103 could be an effective medicine for the treatment of blood diseases, such as polycythaemia vera (PCV), essential thrombocythemia (ET), etc.  PB1103 provides synergistically increased antiviral activity and enhanced pharmacological properties and has been demonstrated to be superior to the commercial Pegylated interferon-alfa in animal studies. 

BioSynersys™ Technology
PBI’s BioSynersys™ technology is available for partnership or licensing for application to biological drugs to develop new generation Synergy PEG-enhanced drugs with the potential to be the next breakthrough therapeutic.

ProbioTherapeutic™ Technology
PBI’s ProbioTherapeutic™ technology is a new site-specific conjugation technology that provides (i) retention of 100% activity of biologics in vivo, (ii) increased biologics’ bioavailability in blood plasma, (iii) increased solubility of biologics, (iv) improved stability of biologics, and (v) increased half-life of biologics. ProbioTherapeutic™ technology is available for licensing and partnership for application to peptides and biologics to develop improved drug formulations and potentially develop the next breakthrough therapeutics.

Alliances

PEG Biosciences is proud of working with our strategic partners to ensure the best expertise is applied to our technologies and drug development.

Rutgers Cancer Institute of New Jersey (CINJ).
Rutgers Cancer Institute of New Jersey is the National Cancer Institute-designated Comprehensive Cancer Center and is recognized as one of the nation’s premier research and clinical cancer treatment centers.  PEG Biosciences works with CINJ in the area of immuno-oncology to transform research into clinical medicine.

Rutgers Brain Health Institute (BHI) and Rutgers Endocrine Research.
The BHI is an interdisciplinary institute at Rutgers University, and has outstanding strength and a broad range of research interests in the area of neurodegeneration, motivational & affective neuroscience, cognitive & sensory neuroscience, and neurodevelopment. PEG Biosciences works with BHI and Endocrine Research to develop medicines for the treatment of disease-related neuroscience, including pain, opioids and alcohol addictions, neuro disorders and neurodegenerative diseases.

Tulane Microbiology, Immunology and Virology Department /Tulane National Primate Research Center.
Tulane National Primate Research Center (TNPRC) improves human and animal health through basic and applied biomedical research. As one of the seven National Primate Research Centers funded by the National Institute of Health, the TNPRC is committed to discovering causes, preventions, treatments, and cures that allow people around the world to live longer, healthier lives.

Business Development and Partnerships
bd@pegbiosciences.com

Career

PBI is committed to saving and improving lives around the world. We are passionate
about developing innovative medicines for patients. At PBI, we recognize talent is our
most important asset. We are constantly looking for skilled and experienced
biotechnology and pharmaceutical professionals, particularly those having expertise in
peptide, nucleotide, protein, drug delivery, or program management. You are
encouraged to send a Cover Letter describing your areas of expertise along with
your recent CV to the following email address:

employment@pegbiosciences.com

Contact

PEG Biosciences
195 Blackhorse Lane, North Brunswick Township, NJ 08902
Tel: 609-933-6158

General Information:
inform@pegbiosciences.com

Partnering and Services: 
bd@pegbiosciences.com